Nano technology tackles heart disease

A molecule designed to find, latch onto, then treat hardened arteries could offer a new way to tackle heart disease, say its inventors.

Nanoburrs, developed at the Massachusetts Institute of Technology (MIT), target only damaged cells in blood vessel walls.                                                                   

Once attached, they can release drugs in precisely the right place.

But the British Heart Foundation warned the technology was some years from being used in patients.

The hardening of the arteries which supply the heart, or atherosclerosis, can eventually lead to blockages which can cause heart attacks.

The study in the Proceedings of the National Academy of Sciences journal says specialists normally use tiny balloons to force open the vessels, then place a tube called a stent inside to keep it open.

Often the process triggers a rapid re-growth of tissue around the stent which can lead to the artery blocking again, and a recent advance has been a stent which releases drugs for a number of days after insertion to keep this process under control.

The MIT approach offers another way to get these drugs to exactly the right place.

Its nanoburrs are coated with proteins which can only stick to a structure in the blood vessel wall called the "basement membrane".

This is only exposed when the wall is damaged, so only damaged sections of blood vessel are targeted.

Once in place, a reaction takes place to release the drug over a prolonged period - up to 12 days so far.

Long way off

Professor Robert Langer, one of the authors of the research, said: "This is a very exciting example of nanotechnology and cell targeting in action."

He said the technology could target any condition in which the cell wall was compromised in this way, including certain types of cancer, and other inflammatory diseases.

Professor Peter Weissberg, medical director of the British Heart Foundation, said that while the technology was "promising", there were many time-consuming obstacles to overcome before it could be regularly used in patients.

He said: "This is an interesting proof of principle. People have been looking for a long time for ways to target a particular drug to a particular part of the body.

"It wouldn't be able to replace the need for a balloon and stent to open an artery, but it's possible that one day, it may be able to deliver a drug to treat atherosclerosis itself."

No such thing as 'safe' cocaine, experts warn

The image of cocaine as a "safe party drug" is a myth that must be dispelled, say UK experts, as a study shows the drug is linked to 3% of sudden deaths.

The British Heart Foundation said the findings, published in the European Heart Journal, were a reminder that the drug can have devastating effects.

Although the data comes from south-west Spain, researchers said the results should apply to Europe in general.

They said anyone could suffer the deadly consequences of taking cocaine.

Fotini Rozakeas of the British Heart Foundation said: "The reality is that there are risks every time you use it.

"Cocaine can have devastating effects on the user including heart attacks, life-threatening heart rhythms, strokes and even sudden death.

"The potential deadly consequences from cocaine use can happen to anyone who takes it, even in previously young healthy people with no history of heart disease."

Deadly cocktail

In the study, 21 out of 668 sudden deaths were related to cocaine use and all of these occurred in men aged between 21 and 45.

Most involved problems with the heart and the majority of the men were also smokers and had been drinking alcohol at the same time as taking cocaine.

Lead researcher Dr Joaquin Lucena, of the Institute of Legal Medicine in Seville, said these habits added up to a lethal cocktail for the heart.

He said: "Our findings show that cocaine use causes adverse changes to the heart and arteries that then lead to sudden death."

His teams looked at post-mortem reports and investigated all the circumstances surrounding sudden deaths in Seville between 2003 and 2006.

Their findings suggested any amount of the drug could be toxic.

"Some patients have poor outcomes with relatively low blood concentrations, whereas others tolerate large quantities without consequences," they told the European Heart Journal.